2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Endocrine
1
Conditions
Melanoma
82
Neoplasms
47
Carcinoma, Non-Small-Cell Lung
28
Colorectal Neoplasms
20
Neoplasm Metastasis
15
Multiple Myeloma
14
Thyroid Neoplasms
13
Glioma
12
Pancreatic Neoplasms
11
Hematologic Neoplasms
10
Thyroid Carcinoma, Anaplastic
9
Brain Neoplasms
8
Lung Neoplasms
7
Triple Negative Breast Neoplasms
5
Skin Neoplasms
5
Rectal Neoplasms
5
Neurofibromatosis 1
5
Lymphoma
5
Leukemia, Myeloid, Acute
5
Colonic Neoplasms
5
Breast Neoplasms
5
Astrocytoma
5
Thyroid Cancer, Papillary
4
Recurrence
4
Prostatic Neoplasms
4
Neurofibroma, Plexiform
4
Glioblastoma
4
Cholangiocarcinoma
4
Biliary Tract Neoplasms
4
Uveal Melanoma
3
Interventions
trametinib
1
dabrafenib
1
Thyrotropin Alfa
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients With RAS or BRAF Mutation
×
trametinib
×
Clear all
NCT03244956
2026-03-23
MERAIODE
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2
Completed
40 enrolled